Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study

Clinical Cancer Research · Published 2026-07-23 · DOI 10.1158/1078-0432.ccr-26-0656

Free full text

Authors (31)

Noushin Niknafs, Lavanya Sivapalan, Archana Balan, Jaime Wehr, Gavin Pereira, Samira Hosseini-Nami, Nisha Rao, Shreshtha Jolly, Kavya Velliangiri, Iiasha Beadles, Tiffany Loftus, Bryan Chesnick, Jamie Medina, Wenming Xiao, Aliyah Pabani, Kristen A. Marrone, Qing Kay Li, Joseph C. Murray, Lorenzo Rinaldi, Nicholas C. Dracopoli, Mark Sausen, Christine L. Hann, Susan C. Scott, Josephine Feliciano, Vincent K. Lam, Benjamin Levy, Victor E. Velculescu, Julie R. Brahmer, Patrick M. Forde, Paz J. Vellanki, Valsamo Anagnostou

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Niknafs, N., Sivapalan, L., Balan, A., et al. (2026). Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-0656

Related articles

• Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial · Clinical Cancer Research · 2026 · Same journal
• Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial · Clinical Cancer Research · 2026 · Same journal
• First-in-human, open-label, single-arm phase 1 study of [211At] meta-astatobenzylguanidine in patients with pheochromocytoma or paraganglioma · Clinical Cancer Research · 2026 · Same journal
• Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in patients with Advanced Hepatocellular Carcinoma · Clinical Cancer Research · 2026 · Same journal
• Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT) · Clinical Cancer Research · 2026 · Same journal
• Preclinical characterization of CLSP-1025, a first-in-class, mutation-specific T-cell engager targeting a neoantigen derived from a common p53 mutation · Clinical Cancer Research · 2026 · Same journal
• Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial · Clinical Cancer Research · 2026 · Same journal
• FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal · Clinical Cancer Research · 2026 · Same journal
• Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight loss (A-NEW) Study · Clinical Cancer Research · 2026 · Same journal
• A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02 · Clinical Cancer Research · 2026 · Same journal